These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 28040352)
1. Re: Phillip J. Gray, Chun Chieh Lin, Matthew R. Cooperberg, Ahmedin Jemal, Jason A. Efstathiou. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol 2017;71:729-37. Gild P; von Landenberg N; Cole AP Eur Urol; 2017 Jun; 71(6):e181-e182. PubMed ID: 28040352 [No Abstract] [Full Text] [Related]
2. Re: MaryBeth B. Culp, Isabelle Soerjomataram, Jason A. Efstathiou, Freddie Bray, Ahmedin Jemal. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol 2020;77:38-52. Patasius A; Smailyte G Eur Urol; 2020 May; 77(5):e132. PubMed ID: 31843337 [No Abstract] [Full Text] [Related]
3. Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682. Shah N; Ioffe V J Urol; 2018 Jul; 200(1):202. PubMed ID: 29596802 [No Abstract] [Full Text] [Related]
4. Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol 2015;68:e110. Stattin P; Robinson D; Lambe M Eur Urol; 2015 Nov; 68(5):e110. PubMed ID: 26184974 [No Abstract] [Full Text] [Related]
5. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol 2022;82:341-51. Sirufo MM; Ginaldi L; De Martinis M Eur Urol; 2023 Apr; 83(4):e102. PubMed ID: 36670032 [No Abstract] [Full Text] [Related]
6. Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30. Ost P; Bossi A; De Meerleer G Eur Urol; 2010 Sep; 58(3):e33; author reply e34-5. PubMed ID: 20537787 [No Abstract] [Full Text] [Related]
7. Re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87. Yang L; Qiu S; Wei Q Eur Urol; 2017 Feb; 71(2):e49-e50. PubMed ID: 27451134 [No Abstract] [Full Text] [Related]
8. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007. Wei Y; Ye D; Zhu Y Eur Urol; 2022 Aug; 82(2):e51. PubMed ID: 35599186 [No Abstract] [Full Text] [Related]
9. Re: Elizabeth J. Schafer, Ahmedin Jemal, Daniel Wiese, et al. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur Urol. 2023;84:117-26. Hsiao PR; Sung WW Eur Urol; 2023 Oct; 84(4):e92. PubMed ID: 37482514 [No Abstract] [Full Text] [Related]
10. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87. Bayne CE; Williams -B; Chapin BF Eur Urol; 2017 Feb; 71(2):e51. PubMed ID: 27461403 [No Abstract] [Full Text] [Related]
11. Re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60. Tolkach Y; Kuczyk M; Imkamp F Eur Urol; 2014 Dec; 66(6):e115-6. PubMed ID: 25139198 [No Abstract] [Full Text] [Related]
12. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6. Sun Y; Sun F; Wei Q; Huang J; Duan R Eur Urol; 2021 Jan; 79(1):e14-e15. PubMed ID: 33121827 [No Abstract] [Full Text] [Related]
13. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6: Prebiopsy MRI: Through the Looking Glass. van den Bergh RCN; Rouvière O; van der Kwast T; Eur Urol; 2020 Sep; 78(3):310-313. PubMed ID: 32660749 [No Abstract] [Full Text] [Related]
14. Reply to Yuri Tolkach, Markus Kuczyk, Florian Imkamp's letter to the editor re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60. Klein EA; Cooperberg MR; Carroll PR Eur Urol; 2014 Dec; 66(6):e117-8. PubMed ID: 25150174 [No Abstract] [Full Text] [Related]
15. Re: Scott P. Kelly, Philip S. Rosenberg, William F. Anderson, et al. Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol 2017;71:195-201. Brookman-May SD; May M; Lebentrau S; Klotz T Eur Urol; 2017 May; 71(5):e145-e146. PubMed ID: 28008855 [No Abstract] [Full Text] [Related]
16. Reply to Yi Sun, Fengxiang Sun, Qiang Wei, Jin Huang, and Ruiqi Duan's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6. Vickers A; Carlsson SV; Cooperberg M Eur Urol; 2021 Jan; 79(1):e16. PubMed ID: 33153816 [No Abstract] [Full Text] [Related]
17. Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6. Prebiopsy MRI: Through the Looking Glass. Vickers A; Carlsson SV; Cooperberg M Eur Urol; 2020 Sep; 78(3):314-315. PubMed ID: 32631742 [No Abstract] [Full Text] [Related]
18. Re: Anobel Y. Odisho, Anna B. Berry, Ardalan E. Ahmad, Matthew R. Cooperberg, Peter R. Carroll, Badrinath R. Konety. Reflex immunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.019. Prakash J; Goel A; Garg M Eur Urol; 2012 Nov; 62(5):e87; author reply e88. PubMed ID: 22902038 [No Abstract] [Full Text] [Related]
19. Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. Eur Urol 2016;69:58-9: Which patients need treatment intensification? Dal Pra A; Spahn M Eur Urol; 2016 Apr; 69(4):e74-e75. PubMed ID: 26508311 [No Abstract] [Full Text] [Related]
20. Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Polascik J Urol 2018; 200: 758-766. Wang CS; Jhan JH; Li CC J Urol; 2019 Mar; 201(3):627-628. PubMed ID: 30759714 [No Abstract] [Full Text] [Related] [Next] [New Search]